Tirzepatide Wholesale & Bulk Supply Guide

Define the Tirzepatide supply format

A useful wholesale inquiry identifies the required vial specification, quantity, packaging and destination. Review current vial formats on the Tirzepatide wholesale supplier page.

Prepare a wholesale or bulk inquiry

Send the specification, quantity, destination country and documentation requirements. This gives the supply team enough information to confirm the relevant packaging, lead time and quotation scope.

• Required specification
• Quantity or box count
• Destination country
• Packaging or private-label requirement
• COA and batch-document requirements

Review documentation before confirmation

Match the material, proposed batch and analytical documentation before approving the order. The LotusBio COA library includes representative raw-material documentation and additional reports can be requested by product and batch.

Tirzepatide API and raw material sourcing

For bulk Tirzepatide API or raw-material requirements rather than finished vial formats, use the dedicated Tirzepatide API supplier page. Specify the total mass, supplied form and container requirements for a raw-material inquiry. A vial report does not establish the identity or quality of a different raw-material batch.

Tirzepatide wholesale inquiry example

This example shows how to specify a research procurement request. It is not a confirmed order, stock statement or minimum quantity.

Catalog item

TR60 — 60 mg per vial, 10 vials per box

Requested quantity

2 boxes — 20 vials at the selected label quantity

Information to add

Destination country, required date, packaging preference and documentation requirements

Ask the quotation to identify the proposed batch, available report, minimum quantity, preparation time and shipping terms. If multiple strengths are required, list each catalog code and box count as a separate line. Prices are provided by quotation.

Worked example: reviewing the TR30 Janoshik record

The original Janoshik report #213592 identifies sample TR30 and batch CP01260707130L, with analysis conducted on 6 August 2026. It reports 30.27 mg Tirzepatide content and 99.669% purity for that sample.

1. Match the report number and sample reference to the original laboratory record.
2. Compare the printed batch with the batch proposed in the quotation; the catalog code alone is insufficient.
3. Read content and purity as separate results. Neither value establishes unreported tests or the quality of another batch.
4. If the proposed batch differs, request its own applicable documentation.

See the Tirzepatide product report section for a preview and additional verification links. For molecular identity and research evidence, read the Tirzepatide research guide.